Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

S Francque, G Szabo, MF Abdelmalek… - Nature reviews …, 2021 - nature.com
The increasing epidemic of obesity worldwide is linked to serious health effects, including
increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic …

Causes and consequences of hypertriglyceridemia

CJ Packard, J Boren, MR Taskinen - Frontiers in endocrinology, 2020 - frontiersin.org
Elevations in plasma triglyceride are the result of overproduction and impaired clearance of
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …

The dawn of a new era of targeted lipid-lowering therapies

L Tokgözoğlu, P Libby - European heart journal, 2022 - academic.oup.com
Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control
of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless …

Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases

S Yamashita, D Masuda, Y Matsuzawa - Current atherosclerosis reports, 2020 - Springer
Abstract Purpose of Review Reduction of serum low-density lipoprotein cholesterol (LDL-C)
levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) …

PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH)

S Todisco, A Santarsiero, P Convertini, G De Stefano… - Biology, 2022 - mdpi.com
Simple Summary In the context of liver disease, one of the more growing public health
problems is the transition from simple steatosis to non-alcoholic steatohepatitis. Profound …

Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease

A Fougerat, A Montagner, N Loiseau, H Guillou… - Cells, 2020 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently
associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease …

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

L Wang, Y Cai, L Jian, CW Cheung, L Zhang… - Cardiovascular …, 2021 - Springer
The prevalence of cardiomyopathy is higher in diabetic patients than those without diabetes.
Diabetic cardiomyopathy (DCM) is defined as a clinical condition of abnormal myocardial …

Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care

GF Watts, SS Gidding, P Mata, J Pang… - Nature Reviews …, 2020 - nature.com
Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention

DT Michaeli, JC Michaeli, S Albers, T Boch… - American Journal of …, 2023 - Springer
Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …

PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients

NF Lange, V Graf, C Caussy, JF Dufour - International journal of …, 2022 - mdpi.com
Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of
the nuclear hormone receptor superfamily, have been identified as key metabolic regulators …